Treatment of primary Sjögren's syndrome with hydroxychloroquine☆
References (34)
- et al.
Extrasalivary lymphoid abnormalities in Sjögren's syndrome
Am J Med
(1967) - et al.
Immunosuppressive potential of antimalarials
Am J Med
(1983) Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy
Am J Med
(1983)Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment
Am J Med
(1983)- et al.
Two types of mouse helper T cell clone
- et al.
A common idiotype on human rheumatoid factors identified by a hybridoma antibody
Mol Immunol
(1983) - et al.
Primary Sjögren's syndrome: clinical and immunopathologic features
Semin Arthritis Rheum
(1984) - et al.
Sjögren's syndrome
- et al.
Sjögren's syndrome 2
Clin Assoc Quart J Med
(1973) - et al.
Sjögren's syndrome: proposed criteria for classification
Arthritis Rheum
(1986)
Increased risk of lymphoma in sicca syndrome
Ann Intern Med
High incidence of free light chains in the sera of patients with Sjögren's syndrome
J Immunol
Non IgM monoclonal gammopathy in patients with Sjögren's syndrome
Am J Med
Expression of a cross reactive idiotype on rheumatoid factor in patients with Sjögren's syndrome
J Immunol
A postgraduate lecture of lupus erythematosus
Clin J
A controlled study of chloroquine as an antirheumatic agent
Arthritis Rheum
The value of chloroquine in rheumatoid disease
Cited by (100)
Electrochemical sensor based on a chitosan-molybdenum vanadate nanocomposite for detection of hydroxychloroquine in biological samples
2022, Journal of Colloid and Interface ScienceCitation Excerpt :Hydroxychloroquine sulfate (HCQ, 2-[4-[(7-chloroquinolin-4-yl) amino] pentyl-ethylamino] ethanol; sulfuric acid) is first established to treat malaria disease [1]. The observational data illustrate that HCQ molecules have also high clinical experience for the chronic inflammatory disorders like rheumatoid arthritis [2], sjogren’s syndrome [3] and lupus erythematosus [4]. Although its antiviral activity against severe acute respiratory syndrome β-coronavirus (SARS-CoV-2) provides an amplified immune response to coronavirus-related disease, the efficacy mechanisms of HCQ on immune-modulating system of host receptors are still being studied [5,6].
Sjögren's Syndrome
2017, The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic ApproachesNew Treatment Guidelines for Sjögren's Disease
2016, Rheumatic Disease Clinics of North AmericaRecommendations for the treatment of Sjögren's syndrome
2015, Revista Brasileira de ReumatologiaSjögren's Syndrome
2013, Women and Health
- ☆
This work is supported in part by NIH grants AR 33983 and RR 00833. This is publication number 5162BCR from the Research Institute of Scripps Clinic, La Jolla, California.